References
- Barahona Afonso AF, Joao CM. The production processes and biological effects of intravenous immunoglobulin. Biomolecules 2016;6:15.
- Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma—aspects of yield and virus safety. Biotechnol J 2006;1:148–63.
- Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28:737–64.
- Greenbaum BH. Differences in immunoglobulin preparations for intravenous use: a comparison of six products. Am J Pediatr Hematol Oncol 1990;12:490–6.
- Branch DR. Unraveling the IVIG mystique. Transfusion 2013;53:242–4.
- Schroeder HW Jr, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection 2012;40: 601–11.
- Imbach P, Barandun S, d’Apuzzo V, et al. High dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228–31.
- Imbach P, Morell A. Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Int Rev Immunol 1989;5:181–8.
- Schwartz SA. Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol 1990;10: 81–9.
- Chipps E, Skinner C. Intravenous immunoglobulin: implications for use in the neurological patient. J Neurosci Nurs 1994;26:8–17.
- Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 2017;139:S1–S46.
- Pendergrast J, Binnington B, Tong TN, et al. Incidence and risk factors for IVIG-mediated hemolysis. Blood 2017;130:2398.
- Branch DR. Anti-A and anti-B: what are they and where do they come from? Transfusion 2015;55(Suppl 2):S74–9.
- Quinti I, Pulvirenti F, Milito C, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion 2015;55:1067–74.
- Michelis FV, Branch DR, Scovell I, et al. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Transfusion 2014;54: 681–90.
- Branch DR, Hellberg A, Bruggeman CA, et al. ABO zygosity, but not secretor or Fc status, is a significant risk factor for IVIG-associated hemolysis. Blood 2018;131:830–5.
- Hoefferer L, Glauser I, Gaida A, et al. Isoagglutinin reduction by dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. Transfusion 2015;55(Suppl 2):S117–21.
- Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013; 105:54–64.
- Puga Yung G, Seebach JD, Baerenzung N, Pendergrast J, Cserti-Gazdewich C, Branch DR. IgG subclasses determined from eluates of DAT positive patients after high-dose IVIg therapy do not predict hemolysis and are primarily of the IgG2 subclass. Transfusion (in press).
- Moscow JA, Casper AJ, Kodis C, Fricke WA. Positive direct antiglobulin test results after intravenous immune globulin administration. Transfusion 1987;27:248–9.
- Robertson VM, Dickson LG, Romond EH, Ash RC. Positive antiglobulin tests due to intravenous immunoglobulin in patients who received bone marrow transplant. Transfusion 1987;27:28–31.
- Whitsett CF, Pierce JA, Daffin LE. Positive direct antiglobulin tests associated with intravenous gamma globulin use in bone marrow transplant recipients. Transplantation 1986;41: 663–4.
- Thorpe SJ, Fox B, Heath A, Behr-Gross M-E, Virata ML, Yu M-Y. International collaborative study to assess candidate reference preparations to control the level of anti-D in IVIG for use in Europe and the United States. Biologicals 2006;34: 209–12.
- Sakem B, Matozan K, Nydegger UE, Weigel G, Griesmacher A, Risch L. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations. Isr Med Assoc J 2013;15:617–21.
- Thorpe SJ, Fox BJ, Dolman CD, Lawrence J, Thorpe R. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. Vox Sang 2003;85:80–4.
- Turner CE, Thorpe SJ, Brasher MD, Thorpe R. Anti-Rh D activity of commercial intravenous immunoglobulin preparations. Vox Sang 1999;76:55–8.
- Garratty G. Problems associated with passively transfused blood group alloantibodies. Am J Clin Pathol 1998;109: 769–77.
- Lucas GS, Jobbins K, Bloom AL. Intravenous immunoglobulin and blood-group antibodies. Lancet 1987;2:742.
- Romer J, Morgenthaler J-J, Scherz R, Skvaril F. Characterization of various immunoglobulin preparations for intravenous application I: protein composition and antibody content. Vox Sang 1982;42:62–73.
- Kluge A, Dopfer R, Pfeiffer-Wolf I, Roelcke D. Immunoglobulin high-dose therapy: RBC-alloantibodies in commercial preparations and haemolytic anaemia: a case report. Beitr Infusionsther Transfusionsmed 1994;32:474–5.
- Lichtiger B, Rogge K. Spurious serologic test restuls in patients receiving infusions of intravenous immune gammaglobulin. Arch Pathol Lab Med 1991;115:467–9.
- Garcia L, Huh YO, Fischer HE, Lichtiger B. Postivie immunohematologic and serologic test results due to high dose intravenous immune globulin administration. Transfusion 1987;27:503.
- Steiner EA, Butch SH, Carey JL, Oberman HA. Passive anti-D from intravenous immune serum globulin. Transfusion 1983;23:363.
- Hoppe I. Antibody screening of commercially available immunoglobulins. erythrocyte-, HLA- and autoantibodies. Blut 1979;39:9–16.
- Lang GE, Veldhuis B. Immune serum globulin—a cause for anti-Rh(D) passive sensitization. Am J Clin Pathol 1973;60:205–7.